Robust signals of clinical efficacy, with ORR of 83%, of which 67% are CR/CRiFive patients with responses longer than 1 yearLongest remission 858 days, still ongoingRapid onset of responses (TTR 29 days)Iadademstat and azacitidine combination shows a good safety profile MADRID, Spain and CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with s